We assessed the longitudinal alteration of the quality of life (QOL) of patients with localized prostate cancer after radical prostatectomy or hormonoradiotherapy during 3-y follow-up. In addition, we examined the impact on QOL of initiation of second treatment after failure of primary treatment. In all, 135 patients with localized prostate cancer who underwent radical retropubic prostatectomy (RP) (N ¼ 84) or external beam radiotherapy with neoadjuvant hormone (XRT) (N ¼ 51) at our institute and who had a minimum follow-up of 3 y were included in this study. Data were collected prospectively, at baseline, at 3 months after treatment, at 1 y, and annually thereafter. QOL, generic and disease-targeted was evaluated using the European Organization for Research and Treatment of Cancer Prostate Cancer QOL Questionnaire, the Sapporo Medical University Sexual Function Questionnaire, the International Prostate Symptom Index Quality of Life Score and similar questions regarding bowel function. Repeated-measures ANOVA revealed significantly different patterns of alteration in the domains of QOL, with the exception of several domains, between the RP and XRT groups. Rapid decline of sexual function and increase in sexual bothersomeness were followed by slight amelioration throughout follow-up in the RP group, and did not change thereafter in the XRT group. Overall satisfaction with urinary condition significantly improved after treatment and that with bowel condition was stable during followup in both of the groups. Failure of primary treatment and initiation of salvage treatment had no impact on QOL. This prospective study revealed longitudinal alteration of QOL status of patients undergoing treatment for localized prostate cancer, but did not yield any conclusions regarding effect of treatment failure and second treatment on QOL due to small sample size. It should be noted that different instruments for assessment of QOL can generate different outcomes.
Introduction
In recent years, screening for prostate cancer has promoted detection of disease at an earlier stage. Since locally confined prostate carcinoma rarely exhibits rapid progression, it is likely that patients with localized prostate cancer can live long lives. Thus, health-related quality-of-life effects may play a crucial role in determining choice of treatment.
The standard treatment options for localized prostate cancer in Japan include radical prostatectomy and external-beam radiation. It is known that prostatectomy can induce urinary incontinence and erectile dysfunction due to damage to the urinary sphincter and cavernous nerve. 1, 2 Irradiation therapy is associated with bladder irritability, rectal irritability, and erectile dysfunction. 3 While these treatment options directly influence quality of life (QOL), especially several disease-specific domains including urinary, bowel, and sexual conditions, longterm follow-up may reveal impacts of other factors such as salvage therapy for initial treatment failure and initiation of second treatment.
Many studies published in the past decade examined the QOL of patients with localized prostate cancer, and we also previously reported short-term changes of QOL of patients undergoing radical prostatectomy. 4 However, most of these studies were retrospective, cross-sectional, or short-term prospective ones. Further, most of the studies reported previously used the Medical Outcome Study Short Form-36 (SF-36) 5 and the University of California at Los Angeles Prostate Cancer Quality of Life Index (UCLA PCI) 6 as modalities for evaluation of QOL. These questionnaires are well-constructed and utilized widely throughout the world. However, there is no single perfect questionnaire and each validated questionnaire has different characteristics.
In this long-term prospective study with a minimum follow-up of 3 y, we attempted despite the small size of the study population to examine the following two issues: first, longitudinal alteration of QOL after treatment, and second, the impact of initiation of second treatment on QOL after failure of primary treatment. Since we conducted this study using the European Organization for Research and Treatment of Cancer Prostate Cancer QOL Questionnaire (EORTC-P) 7 and the Sapporo Medical University Sexual Function Questionnaire (SMUSFQ), 8 our study may yield findings other than studies performed with the SF-36 and UCLA PCI.
Materials and methods
Between April 1996 and October 2000, a total of 167 men with localized prostate cancer received treatment with radical retropubic prostatectomy (RP) or external radiation therapy (XRT) at our institute. After informed consent, 135 patients (81%) participated in this study. Of the 135 patients, 84 underwent RP and 51 underwent XRT. The questionnaires mentioned below were answered by the participants before treatment, 3 months and 1 y after treatment, and annually thereafter. They were staged with digital rectal examination, transrectal ultrasound (TRUS), abdominal computed tomography, and bone scan, according to the 1992 UICC staging system. All patients underwent prostate-specific antigen (PSA) determination before prostate biopsy.
Basically, we recommended retropubic radical prostatectomy if the patient was 75 y of age or younger and had a tumor with a clinical stage of cT2c or lower, and recommended XRT with neoadjuvant hormone therapy if the patient was older than 75 y and/or had a tumor with clinical stage of cT3a or higher. However, final determination of treatment modality was made by the patient after thorough discussion of options including watchful waiting.
Of 84 patients in the RP group, 10 received neoadjuvant hormone therapy 3-6 months prior to RP. Of 10 patients receiving preoperative hormone therapy, seven had clinical T3 disease. One of the remaining three patients had clinical T2 and the other two had clinical T1c disease with high serum PSA level of 31-97 ng/ml. Although usefulness of neoadjuvant hormone therapy is questionable at present, it was considered a permissible option for locally advanced prostate cancer during this entry period. The procedure of RP was essentially the same as that originally described by Walsh. The cavernous nerve was spared bilaterally in 26 patients, and unilaterally in 39. Pelvic lymph node dissection was routinely performed. Three of us (YA,KY,KO) performed all operations. Of 51 patients in the XRT group, all received neoadjuvant hormone therapy using leuprolide or goserelin. Median duration from hormone therapy to radiation was 6.7 months. All of these patients underwent external beam radiation to a total of 66 Gy with the conventional method.
Our definition of PSA failure was as follows: (1) in the RP group, PSA nadir above 0.1 ng/ml, or three consecutive PSA increases from nadir below 0.1 ng/ml, (2) in the XRT group, three consecutive PSA increases after 1-year from termination of radiation therapy.
QOL methodology
The primary health-related QOL measure used was the Japanese version of the European Organization for Research and Treatment of Cancer Prostate Cancer Quality-of-Life Questionnaire (EORTC-P), which was validated by Isaka et al. 9 The questionnaire consists of 32 items grouped into the following scales: physical functioning (PF, eight items); physical symptoms (PS, nine items); fatigue/malaise (FM, five items); sexual problems (SP, three items); psychological distress (PD, five items); and impact of the disease on family/social life (ID, two items). Subscale scores were the sum of the items in each domain. In addition to the 32-item scale, the Face Scale, prepared with some modification from the original form reported by Lorish and Maisiak, 10 contains five drawings of a single face arranged in decreasing order of mood and numbered from 1 to 5, with 1 representing the most positive mood and 5 representing the most negative mood.
Disease-targeted measures were used to address the level of function or amount of bothersomeness of sexual, urinary, and bowel functions. To evaluate sexual function, we used the questionnaire developed by researchers at the Sapporo Medical University School of Medicine (SMUSM), which has been validated in more than 5000 adult Japanese men. 8 It concerns sexual desire, ability to have an erection, and quality of sexual activity, as we previously described. To evaluate amount of comprehensive bothersomeness of urinary function, we used the International Prostate Symptom Score quality of life (I-PSS QOL) score. 11 We also used other questions related to stress incontinence and number of pads use (Appendix A). The questionnaire consisted of two questions, as follows: (1) does coughing and/or sneezing induce leakage of urine? (2) How many pairs of underwear or pads do you need to use because of leakage of urine? These questions were answered using a five-grade scale. To evaluate comprehensive amount of bothersomeness related to bowel function, we used a similar question with a six-point scale, 'If you were to spend the rest of your life with your bowel symptoms just as they are now, how would you feel about that?'. We used other questions on bowel bleeding, bowel irritability, and pain around the anal area in accordance with the questionnaire presented by Bordhede et al.
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Analyses and statistics
At baseline, comparison between the two treatment groups was performed with an unpaired t-test or w 2 test. Scores of the aforementioned dimensions of QOL were sequentially plotted, and alterations of them were estimated longitudinally in the RP and XRT groups. These statistical analyses were performed using a paired t-test for each group, and repeated-measures analyses of variance (ANOVA) to compare effects of the two treatments.
When we assessed the impact of initiation of second treatment on QOL, we compared the scores of all the dimensions of QOL just before initiation of second treatment and just after it using a paired t-test. P-values o0.05 were considered to indicate statistical significance.
Results
Study population
Although most questions at any time point were answered by over 80% of the study population, the answering rates for questions regarding sexual function were generally low, at 50-70%. The demographic characteristics of the patients are presented in Table 1 . Median follow-up after initiation of primary treatment was 57 months in the RP group and 53 months in the XRT group. During the initial 3-y follow-up period, no patient died of prostate cancer, but one patient in the RP group and one in the XRT group died of other causes. At last follow-up, another patient in the RP group had died due to prostate cancer and two patients in the RP group and six in the XRT group had been lost to follow-up.
Not surprisingly, RP patients were significantly younger, had earlier stage of disease and had lower PSA level than those of the XRT group. In addition, RP patients had higher scores in the 'physical function' domain and several domains of sexual function.
Longitudinal examination of QOL during follow-up
Patterns of alteration of most domains of QOL differed between the two treatment groups (Figures 1-3) . The 'face scale,' 'physical function,' 'sexual desire,' 'overall satisfaction with sex life,' and 'QOL of bowel function' domains were not impacted by differences between treatment modalities.
On the 'face scale,' patients had a significantly more positive mood after treatment than before treatment in both groups. 'Physical function' tended to improve after treatment in both groups, but the differences from baseline were small. Prostatectomy did not affect the 'fatigue/malaise' domain, but radiation therapy reduced 'fatigue/malaise.' 'Psychological distress' diminished gradually after treatment in the RP group. However, in the XRT group, it diminished up to the 1-y point and increased somewhat thereafter. The 'impact of disease' domain improved gradually in the RP group, but again the point of peak improvement was 3 months after treatment in the XRT group.
Sexual functions, which were evaluated using 'sexual problems' in the EORTC-P and SMUSM, exhibited similar patterns of change during follow-up in the two groups. Just after initiation of treatment, all domains except 'overall satisfaction' had deteriorated in the XRT group. In the RP group, 'sexual problems' were worse at 3 months after surgery, were somewhat improved at the 1-y point, and then maintained the same level up to the 3-y point. In the XRT group, initial deterioration in this domain was maintained thereafter. In other domains of sexual function and bothersomeness, except for 'overall satisfaction,' similar tendencies were observed in both groups. On the other hand, regarding 'overall satisfaction,' no regain was observed after initial deterioration in the RP group, and significant deterioration was noted 2 y after radiation in the XRT group.
In the RP group, 'physical symptoms' were unchanged 3 months after surgery, but improved thereafter. In the XRT group, they improved early after initiation of treatment, but deteriorated during the third year of follow-up. While the score for urinary satisfaction assessed by I-PSS QOL score did not change at the 3-month point, significant improvement was observed thereafter in the RP group. On the other hand, each result for stress incontinence and pad use significantly deteriorated after surgery. The average scores for 'stress incontinence' were 0.1 at baseline, 0.8 at 3-months (Po0.001, vs baseline), 0.5 at 1-y (P ¼ 0.042, vs 3-month), and 0.5-0.6 thereafter. The average scores for 'pad use' were 0.0 at baseline, 0.5 at 3-months (Po0.001, vs Quality of life in patients with prostate cancer K Yoshimura et al baseline), 0.2 at 1-y (P ¼ 0.002, vs 3-month), and 0.1-0.2 thereafter. In the XRT group, rapid improvement after therapy was maintained throughout the follow-up in comprehensive QOL related to urination. The scores for 'stress incontinence' and 'pad use' did not change during the study period.
There was no alteration throughout the follow-up in either group in comprehensive QOL related to bowel function. For RP patients, the three individual scores for bowel symptoms exhibited no change during the study period. In XRT patients, the score for 'bowel bleeding' marginally increased from 1.0 at baseline to 1.2 at 1-3 y after treatment (P ¼ 0.055-0.064).
Impact of initiation of second treatment
Of 84 RP patients, 21 suffered from PSA failure and all underwent second treatment. In total, 16 patients received radiation to the vesico-urethral anastomosis Quality of life in patients with prostate cancer K Yoshimura et al and five received hormone therapy. Median time to initiation of second treatment from prostatectomy was 13 months. Of 51 XRT patients, 27 suffered from PSA failure. Of these 27 patients, 15 underwent second treatment during the study period, and the others were placed under observation. The second therapy for these 15 patients was hormone therapy. Median time to second therapy from termination of XRT was 26 months.
There were no changes in any domain of QOL after initiation of second treatment (Table 2 ). This finding was noted for RP patients, XRT patients, and all 36 patients of the two treatment groups undergoing second treatment (data not shown). In addition, there was no difference in any domain at any points of time between the 36 patients with second treatment and the other 99 patients (data not shown).
Discussion
Longitudinal studies of QOL allow clinicians and patients to determine the impact of treatment on QOL over time, and to make reasonable comparisons of various treatments. 13 They can greatly aid the informed decision-making process. RP and external beam radiation therapy are the two most prevalent treatment modalities for localized prostate cancer in Japan. Although the final choice of treatment modalities belonged to patients, many patients with locally advanced cancer underwent XRT in our series, as shown in Table 1 . Since phase III studies with large cohorts demonstrated that combination therapy with radiation and hormone improved the survival of patients with locally advanced prostate cancer compared with radiation monotherapy, 14, 15 we routinely used neoadjuvant LHRH analogue therapy prior to radiation therapy. Our patients received only 66 Gy of radiation, since conformal radiation is not available in our institute. In Japan, few institutes have equipment for conformal radiation.
Our prospective study, despite its small population, revealed sequential alterations of QOL, both generic and disease-specific, induced by the two different treatment modalities. Generic QOL analyses, using the four domains included in the EORTC-P, 'physical function,' 'fatigue/malaise,' 'psychological distress,' and 'impact of disease' plus the 'face scale,' exhibited similar trends in change over time in the two treatment groups. In RP patients, 'face scale,' 'psychological distress,' and 'impact of disease' scores gradually but significantly improved up to 1-2 y after surgery and maintained levels Quality of life in patients with prostate cancer K Yoshimura et al thereafter. These improvements of mainly psychological domains were compatible with those observed in the study of Lee et al 16 using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P). However, Schapira et al 17 reported in their study using the SF-36 that role-physical function exhibited a significant decline at 3 months after prostatectomy and that other domains exhibited no change from baseline up to 1 y after prostatecotmy. Other studies using the SF-36 also reported overall stability in generic domains.
6,18-21 These differences in findings from ours may be due to the differences in instruments used for testing. The SF-36 may not be sensitive in assessing the generic QOL of patients with localized prostate cancer. In our study, 'physical function' exhibited changes similar to those of the psychological domains mentioned above, but its degree of change was marginal. We cannot explain why only the 'fatigue/malaise' domain remained unchanged throughout the follow-up period in this situation. All of the domains evaluated, including not only generic ones but also urinary, bowel, and sexual ones, exhibited no change from the 2-to the 3-y point in RP patients. This finding suggests that the QOL status of RP patients becomes stable by 2 y after prostatectomy.
In XRT patients, the patterns of change over time appeared to be more complex than those in the RP group. Most generic QOL domains improved after treatment. However, 'impact of disease' and 'psychological distress' exhibited significant declines during the first and second follow-up years, respectively. As mentioned below, the 'physical symptom' domain exhibited similar changes. These findings suggest that longitudinal QOL evaluation after radiation requires a period longer than 2 y, which may be sufficient for QOL examination after prostatectomy.
In bothersomeness related to sexual function, RP patients exhibited the typical time course of change reported in previous studies. 19, 22, 23 Rapid declines after surgery were followed by some improvement thereafter, but scores did not return to baseline levels. Several previous studies with the UCLA-PCI revealed similar trends, 19, 22, 23 and we conclude that this pattern of longitudinal change is typical of RP. In our study, XRT patients exhibited rapid declines of sexual function and increase in bothersomeness, and levels did not change thereafter. Litwin et al 22 reported that patients undergoing radiation experienced comparable improvement during the first year and a modest but significant decline during the second year in sexual function. Schapira et al 17 reported gradual decline in sexual function up to 2 y despite lack of change in sexual bothersomeness in patients undergoing radiotherapy. In the study by Lubeck et al, 18 radiotherapy had no impact on sexual function and bothersomeness but hormonal therapy induced marked decline in sexual function. Since our XRT cohort underwent LHRH analogue therapy prior to radiotherapy, rapid deterioration followed by stability can be explained as the combined effect of transient androgen deprivation therapy and radiation therapy.
For assessment of urinary function and bothersomeness, in our study the scores of part of the 'physical symptom' domain in the EORTC-P and I-PSS QOL were used as indicators. In RP patients, these indicators moved similarly during follow-up. The score at 3-months did not differ from that at baseline, but significantly decreased thereafter. This finding indicates that patients undergoing RP are more satisfied with their urinary condition after 1 y after surgery. Lee et al 16 reported that I-PSS total score was significantly lower 1 y after RP than at baseline, although they did not assess QOL related to urinary condition by I-PSS QOL score. Steineck et al 24 reported that the percentage of patients with moderateto-severe I-PSS scores was lower in a prostatectomy group than in a watchful-waiting group, while the percentage of patients with moderate-to-severe distress related to urinary condition was higher in the prostatectomy group than in the watchful-waiting group. Recently, Masters and Rice 25 reported that there was a very significant increase in flow rate and decrease in I-PSS after prostatectomy. On the other hand, studies using the UCLA PCI concluded that RP impaired urinary condition. [17] [18] [19] [20] This discrepancy with regard to our findings was due in part to the difference in instruments used. Although the UCLA PCI focuses on symptoms of irritability and incontinence, it is likely that patients with prostate cancer are bothered by bladder outlet obstruction as well as symptoms of irritability. Since results for our other questions on urinary continence revealed significant deterioration of incontinence after RP, it appeared that release from bladder outlet obstruction greatly contributed to improvement of QOL related to urinary condition. XRT patients had earlier improvement of QOL related to urinary condition. While the decrease of I-PSS QOL score continued up to the 3-y point, 'physical symptom' score slightly, but significantly, deteriorated during the second year of follow-up.
Regarding bowel function, overall satisfaction of patients was unchanged during this study period in both the RP and XRT groups. Results for the question on bowel bleeding revealed marginal deterioration in the XRT group. Although this finding was compatible with the findings reported in previous studies using the UCLA PCI, [17] [18] [19] [20] [21] the finding of stability of comprehensive QOL related to bowel condition in XRT patients may again be due to differences in instruments used. Although the UCLA PCI focuses on irritable bowel symptoms, many individuals in the general population suffer from constipation. Overall satisfaction related to bowel condition may depend both on irritable bowel symptoms and constipation.
In 1996, when this study was initiated, no validated Japanese questionnaire on urinary continence and bowel symptoms for assessment of the conditions of patients with prostate cancer was available. We therefore prepared two questions for urinary continence and utilized three questions for bowel symptoms in accordance with the questionnaire presented by Borghede et al. 12 Since they were not validated for use, the results obtained with them were not conclusive but nevertheless meaningful, as described above.
When follow-up continues for a long period of time, some fraction of patients experience failure of primary treatment. It is very important to assess the impacts on QOL of treatment failure and initiation of salvage treatment. In our series, 48 were diagnosed with PSA failure after primary treatment and 36 of them underwent second therapy. Our study revealed no significant impact on QOL of the initiation of second treatment, but we can conclude nothing from this finding due to the small sample size, which makes avoidance of Type 2
Quality of life in patients with prostate cancer K Yoshimura et al error impossible (data not shown). Further examination of this issue with a larger sample size is warranted. Recently, Lubeck et al 26 reported that patients requiring salvage therapy after radical prostatectomy had poorer QOL than those without salvage therapy at all points during follow-up. Our data are not consistent with their findings.
There are several limitations to our study. This study was based on a relatively small population, and assessment of disease-specific QOL, especially regarding urinary and bowel conditions, was insufficient. Owing to this limitation, potential differences between groups may not have been detected. When we started this study in April 1996, no validated questionnaire on localized prostate cancer with a Japanese translation was available other than the EORTC-P. However, this instrument, together with the I-PSS QOL score, yielded several findings other than those obtained with the UCLA PCI and SF-36. Since there is no single perfect questionnaire regarding QOL issues and different tools disclose different aspects of QOL, it is useful to have various options available for evaluation of the QOL of patients.
